Immune cells help reverse chemotherapy resistance in ovarian cancer
Inside each ovarian tumor, there are good cells and bad cells. A new paper explains their roles:
May 20, 2016
0
78
Inside each ovarian tumor, there are good cells and bad cells. A new paper explains their roles:
May 20, 2016
0
78
A team of Walter and Eliza Hall Institute researchers has worked out how a new class of anti-cancer drugs kills cancer cells, a finding that helps explain how cancer cells may become resistant to treatment.
May 20, 2016
0
101
Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer in Switzerland. Despite intensive chemotherapy, one fifth of the patients suffer a relapse, which usually goes hand in hand with a poor prognosis. ...
May 18, 2016
0
22
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are ...
Apr 21, 2016
0
0
When a freeway shuts down because of an accident or construction, drivers find another road to take them where they're going. Likewise, when a targeted therapy blocks a pathway that enables tumors to grow, the cells usually ...
Apr 11, 2016
0
1
The occurrence of chemotherapy resistance is one of the major reasons for failure in cancer treatment. A study led by Óscar Fernández-Capetillo, Head of the Genomic Instability Group at the Spanish National Cancer Research ...
Apr 7, 2016
0
3
A metabolic pathway that is up-regulated in certain breast cancers promotes the disease's progression by activating a cell signaling protein called Arf6, according to a paper published in the Journal of Cell Biology. The ...
Apr 6, 2016
0
24
Combining a new synthetic apigenin compound with existing anticancer drug treatments can reverse drug resistance, say researchers at The Hong Kong Polytechnic University (PolyU). The compound can also improve the absorption ...
Apr 5, 2016
0
12
Breast cancer cells became resistant to therapeutics targeting CDK4/6, such as palbociclib (Ibrance), in multiple ways, and preclinical studies suggested different combinations of therapeutics may prevent and overcome the ...
Mar 28, 2016
0
6
Moffitt Cancer Center researchers discovered that patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival. That's according ...
Mar 18, 2016
0
0